Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Rein Therapeutics, with one sell, one hold, and two buy recommendations. The average 12-month price target is $6.00.
• RNTX opened at $0.89, versus a 52-week range of $0.69 to $2.18, and has a market capitalization of approximately $76.7 million. The company’s latest quarterly loss of $0.10 per share was narrower than the $0.27 consensus estimate.
• Institutional investors own 90.89% of the stock, while recent buyers included Susquehanna International Group, HRT Financial, and Jane Street. Rein Therapeutics is developing the RT-101 IL-12 prodrug for solid tumors, including head and neck cancer and non-small cell lung cancer.

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) have earned an average recommendation of "Hold" from the four research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.00.

Several equities analysts have commented on RNTX shares. HC Wainwright reiterated a "buy" rating on shares of Rein Therapeutics in a report on Tuesday, August 18th. Weiss Ratings cut shares of Rein Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 21st. Maxim Group began coverage on shares of Rein Therapeutics in a report on Monday, July 20th. They set a "buy" rating and a $4.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Rein Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th.

Rein Therapeutics Stock Performance

RNTX opened at $0.89 on Tuesday. The stock has a fifty day moving average price of $0.84 and a 200 day moving average price of $1.09. Rein Therapeutics has a 1 year low of $0.69 and a 1 year high of $2.18. The stock has a market cap of $76.70 million, a price-to-earnings ratio of -0.52 and a beta of 1.37.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, sell-side analysts forecast that Rein Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rein Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in RNTX. Susquehanna International Group LLP acquired a new position in shares of Rein Therapeutics during the 3rd quarter worth about $35,000. HRT Financial LP acquired a new stake in Rein Therapeutics in the 4th quarter valued at approximately $38,000. Chicago Partners Investment Group LLC increased its position in Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company's stock worth $53,000 after buying an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Rein Therapeutics during the second quarter worth approximately $68,000. Finally, Jane Street Group LLC acquired a new position in shares of Rein Therapeutics during the fourth quarter worth approximately $72,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.